Although research on metabolic changes has improved our understanding of KRAS-mutation-driven CRC, the precise mechanism by which metabolic reprogramming promotes and coordinates KRAS-mutant CRC progression remains to be fully elucidated. This evidence concerns the gene KRAS and colorectal carcinoma.